Cargando…
Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model
A therapeutic approach to improve treatment outcome of ovarian cancer (OC) in patients is urgently needed. Myxoma virus (MYXV) is a candidate oncolytic virus that infects to eliminate OC cells. We found that in vitro MYXV treatment enhances cisplatin or gemcitabine treatment by allowing lower doses...
Autores principales: | Nounamo, Bernice, Liem, Jason, Cannon, Martin, Liu, Jia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573804/ https://www.ncbi.nlm.nih.gov/pubmed/28875159 http://dx.doi.org/10.1016/j.omto.2017.08.002 |
Ejemplares similares
-
Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes/macrophages
por: Conrad, Steven J., et al.
Publicado: (2022) -
Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma
por: Christie, John D., et al.
Publicado: (2022) -
Optimization of a syngeneic murine model of bone metastasis
por: Farhoodi, Henry P., et al.
Publicado: (2020) -
Dual-Armed Oncolytic Myxoma Virus Encoding IFN-γ and CD47 Promotes Lymphocyte Infiltration and Tumor Suppression of Syngeneic Murine Melanoma
por: Woo, Jong Kyu, et al.
Publicado: (2023) -
Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer
por: Russell, Shonagh, et al.
Publicado: (2022)